Drug Trial Radar · NCT00702845
To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)
Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
397
Actual
Start
Dec 28, 2006
Primary completion
Jul 7, 2007
Study completion Nov 15, 2007
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Jun 20, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 36 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical trial objectives are to investigate the efficacy and safety of a single injection of 100 μg Org 36286 in women weighing 60 kg or less to induce multifollicular development for controlled ovarian stimulation (COS), using daily recFSH as a reference.
Conditions
- Infertility
Interventions
corifollitropin alfa (Org 36286)Drug
100 µg corifollitropin alfa subcutaneous (SC) injection
recFSH (follitropin beta)Drug
150 IU recFSH SC injection
gonadatropin releasing hormone (GnRH) antagonist (ganirelix)Drug
GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
human chorion gonadatropin (hCG)Drug
hCG 5,000 IU or 10,000 IU administered SC
progesteroneBiological
Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
placebo-recFSH (follitropin alfa)Drug
Placebo-recFSH administered at the equivalent volume of 150 IU/day.
placebo-corifollitropin alfaDrug
Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
open-label recFSHBiological
Open-label recFSH administered up to a maximum dose of 200 IU/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Cumulus-oocyte-complexes Retrieved, Per AttemptTime frame: One COS cycle with cumulus-oocyte-complex retrieval (up to a maximum total duration of 21 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.